Program
VX-828
A development code.
Its studies are mostly in Cystic Fibrosis, led by Vertex Pharmaceuticals.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Vertex Pharmaceuticals | 20 open or running | phase 1since Nov 23, 2023 | Nov 23, 2023 | none ahead |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Nov 23, 2023First study: phase 1 study in Cystic FibrosisFirst studyNCT06154447 · 165 enrolled · United States
- Feb 28, 2025Phase 1 study in Cystic FibrosisNCT06861413 · 68 enrolled · United States
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 2 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT06861413Cystic Fibrosis · United States | 1 | Completed | May 5, 2025 | 68 |
| NCT06154447Cystic Fibrosis · United States | 1 | Completed | Jul 10, 2026 | 165 |
How it is read
Names in the registry
- “VX-828”, 4 entries
Codes read as this program: VX828.
Conditions, from the studies’ own filings
- Cystic Fibrosis, 2 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.